Eight weeks of treatment with AbbVie’s Mavyret (glecaprevir/pibrentasivr) cured all those with genotypes 1, 2, 4, 5 and 6 of hepatitis C virus (HCV) and compensated cirrhosis in a recent trial. Current guidelines call for 12 weeks of treatment.

Presenting their findings at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco (The Liver Meeting), researchers enrolled 280 people with genotypes 1, 2, 4, 5 and 6 and compensated cirrhosis (the milder form of the advanced liver disease) in the nonrandomized, single-arm, open-label multicenter Phase IIIb EXPEDITION-8 study.

The study has another ongoing cohort of people with genotype 3 of hep C and compensated cirrhosis. The results presented at The Liver Meeting concern only the cohort with other genotypes.

Seven of the 280 participants were not included in the analysis of Mavyret’s cure rate. Five of them were lost to follow-up and two received less than eight weeks of treatment (one of them was cured nevertheless).

All 273 of the remaining participants achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure).

Adverse events reported by more than 5 percent of the study population included itching (9.6 percent reported it), fatigue (8.6 percent), headache (8.2 percent) and nausea (6.4 percent).

Six serious adverse events occurred during the study, none of which were deemed related to Mavyret.

To read a press release about the study, click here.